A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01672775
Recruitment Status : Completed
First Posted : August 27, 2012
Last Update Posted : April 17, 2017
Information provided by (Responsible Party):
Astellas Pharma Inc ( Agensys, Inc. )

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : February 21, 2017
  Study Completion Date : February 21, 2017